UB BIG is catalyzing the growth of the life sciences innovation economy in Western New York and helps its partners reach milestones at an accelerated rate.
As a BIG partner, you have access to technical expertise, talent, state-of-the-art facilities, high-tech genomic and proteomic equipment, big data solutions and funding. BIG partners have benefited from this incentive by:
The prevalence of autoimmune diseases is as high as 20%, affecting over 50 million people in the United States. They are associated with significant morbidity and mortality. Early diagnosis of autoimmune diseases is crucial for optimal management.
Aesku NY, Inc. is established with a focus on the development, manufacturing and distribution of in vitro diagnostic reagents and test methods mostly for autoimmune diseases that may be used in combination with Aesku’s proprietary HELIOS system. This system is a fully automated end-to-end for processing of specimens for immuno-fluorescence staining and for interpretation of the results using an algorithm pattern library to give the most accurate diagnosis with the most favorable outcomes for a patient.
Through accessing specialized equipment funded by BIG, Aesku will be able to further their research and manufacturing capabilities to meet the growing market demands of products on the HELIOS system. Aesku is also collaborating with several researchers at the University at Buffalo for the identification and development of novel bio-markers to be incorporated into their product line.
Located within UB’s New York State Center of Excellence in Bioinformatics and Life Sciences, AHRM Inc. is a global contract research organization with a focus on health care informatics, economics and outcomes research. Through advanced analytics, AHRM provides research support services for biotech companies, including those in the pharmaceutical and medical devices industries, as well as clinics and non-profits.
The partnership between BIG and AHRM will facilitate access to the supercomputing cluster at UB’s Center for Computational Research (CCR). AHRM will leverage CCR’s powerful computational resources to structure, parse and analyze de-identified electronic medical records to help better understand problems and answer questions within the health care industry.
Charlotte’s Web Laboratories is the innovation and development hub for Charlotte’s Web Holdings, Inc., the market leader of hemp-derived cannabidiol (“CBD”) wellness products. Charlotte’s Web Labs is taking a biopharma approach to its research, including clinical studies on safe usage, proper dosage, effectiveness, and human clinical trials.
Support from BIG allows Charlotte’s Web Labs to purchase specialized equipment for in-house cell culture work to study gene expression and bioavailability of the company’s products. Bioavailability and gene expression are key to a product’s safety and efficacy, helping to identify how different people will respond to it. The ability to conduct this testing in-house and rapidly iterate on process development saves the company hundreds of thousands of dollars to keep up with the fast-moving CBD industry. In turn, it also enables Charlotte’s Web to bring research and development jobs to Buffalo.
Circuit Clinical personalizes medicine by bringing studies to the physicians that patients know and trust. The company streamlines the process while removing cost for physicians in order to bring new medical solutions to patients.
As part of its engagement with BIG, Circuit Clinical will expand its technology platform and bring software development jobs to Buffalo.
Enhanced Pharmacodynamics, LLC (ePD) is a big data service provider that assists its clients with the design and implementation of model-informed drug development strategies in oncology and other therapeutic areas. ePD works with 60+ clients, ranging from venture biotech startups to government agencies and large pharma.
Through its partnership with BIG, ePD gains access to state-of-the-art computational horsepower at UB’s Center for Computational Research (CCR). This optimizes the team’s computer modeling processes, allowing them to run innovative, advanced machine learning algorithms to significantly scale up their business.
Garwood Medical is an advanced medical device company whose products will positively enhance clinical outcomes related to infection. Through advanced technology and novel designs, Garwood Medical is committed to disrupt the wound care and perio-prosthetic market by advancing infection control through innovation.
A strategic partnership with BIG provides the company with a state of the art research and development site and a robust university engineering team. This public-private partnership will drive Garwood’s and UB’s technologies through development, by performing all aspects of research, device modeling, rational product design and prototyping, focusing on verifications, validations and characterizations of the applications and imbedded technologies.
KSL is a Buffalo-based company advancing translational medicine and improving the delivery of personalized medicine through the development of novel genomic- and proteomic-based diagnostics for cancers and orphan diseases. The company has a robust pipeline of proprietary products and services at various stages of development and regulatory clearance in the United States and the rest of the world.
KSL will have access to biological materials from BIG’s biorepository and is working with UB equipment to develop and validate its genomics-based diagnostics products. The company has an internship program through UB and recruits UB graduates.
Neurovascular Diagnostics is a UB-spinoff biotech company that is developing a low-cost blood test to screen high-risk patients for unruptured brain aneurysms.
A strategic partnership with BIG will support Neurovascular Diagnostics’ R&D efforts by connecting the company to technical expertise and subsidizing the cost of engaging with high-tech facilities at the university. This includes use of the UB biorepository, which will provide blood collection kits, as well as processing and storage services. UB’s Genomics and Bioinformatics Core will be utilized for sequencing work.
Polymer Conversions is a high-precision contract manufacturer that specializes in highly technical, tight-tolerance, Critical to Life™ medical devices and components used to treat patients and save lives.
Through a partnership with UB BIG, Polymer Conversions will invest in new automation solutions that support the company’s growth, reduce waste, and de-risk the manufacturing process—ultimately leading to better products for patients. Automation will also allow the company to supplement a surge in demand and ramp up new programs, creating several new jobs.
Tactiva is a development stage immuno-oncology company with a unique approach to adoptive T-cell therapy. Tactiva's dual enhanced adoptive cell therapy (DEACT™) platform, consists of engineered CD4/CD8 cells which generate a durable supply of CD4 cells with direct anti-tumor activity as well as sustained helper function to CD8 T cell derived TCR-transduced effector T cells. Tactiva Therapeutics is working to develop the next generation of cancer immunotherapies by utilizing a new approach to cell therapy. This type of personalized cancer treatment enhances the patient's immune system ability to tackle the disease.
Tactiva Therapeutics has been a partner to the University at Buffalo’s since January 2017 when it colocated at the New York State Center of Excellence in Bioinformatics and Life Sciences on the Buffalo Niagara Medical Campus.
Through the partnership with the University at Buffalo, Tactiva Therapeutics has received funding support from the UB Center for Advanced Technology in Big Data and Health Sciences that enabled a collaboration with UB’s Genomics and Bioinformatics Core, infrastructure that was funded by BIG in support of Tactiva’s discovery efforts.
The partnership with BIG provides Tactiva Therapeutics with access to equipment for their preclinical development of Tactiva’s DEACTTM platform.
Thermo Fisher Scientific is a globally recognized company serving the life sciences industry. The company’s Grand Island, New York location manufactures products and reagents designed to support cell culture processes, which are used in the development of biologic drugs such as antibodies, gene and cell therapies or vaccines.
Thermo Fisher has benefited from the infrastructure funded by BIG in the program’s early years collaborating with UB’s Genomics and Bioinformatics Core (GBC), Proteomics and Bioanalysis Core (PBC) and Center for Computational Research (CCR) to characterize some of their reagents and proprietary cell lines, understand how to better improve their manufacturing processes and to leverage the computational capacity as a way to parse through large, process-driven datasets.
Through BIG’s support, Thermo Fisher has co-located to UB’s Center of Excellence in Bioinformatics and Life Sciences, where a team of Thermo Fisher scientists are actively working on multi-omics approaches and carrying out collaborative projects with UB experts. The physical proximity of the Thermo Fisher lab to UB’s GBC, PBC, and CCR helps further deepen the collaboration between the University and Thermo Fisher. Thermo Fisher will also leverage BIG support for the acquisition of additional equipment.
ZeptoMetrix® is the industry leader for innovative solutions to challenges in the evolving Infectious Disease Diagnostics market. From assay conception to launch, scientific and operational teams provide customers with comprehensive, performance-oriented and cost-effective products and services that positively impact the field of clinical diagnostics and its contribution to global healthcare.
A partnership with BIG will help the firm expand in this market. Through BIG, ZeptoMetrix has access to a high-tech instrumentation system in UB’s Center of Excellence in Bioinformatics and Life Sciences, where the company leases lab space. ZeptoMetrix expects to create new jobs in the region over five years in addition to hiring UB students as interns and engaging in collaborative research with university scientists on topics that could include oncology diagnostics.